SCHEMBL6538426

SCHEMBL6538426

CCCn1nc(-c2cc(Cl)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MET P08581 1/20 0.39
HTT P42858 1/20 0.38
PDE5A O76074 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
CRHBP P24387 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
CRHR2 Q13324 1/20 0.38
ESR1 P03372 1/20 0.38
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538480 0.94 HSD17B10 (0.44) HSD17B10TP53MEN1KMT2AMAPT
SCHEMBL6539234 0.93 HSD17B10 (0.44) HSD17B10TP53MEN1KMT2ACRHBP
SCHEMBL6538523 0.91 TP53 (0.42) TP53SMN1; SMN2HTTMEN1KMT2A
SCHEMBL6538489 0.87 MEN1 (0.49) TP53SMN1; SMN2HTTPDE5AMEN1
SCHEMBL6539249 0.86 TP53 (0.40) HSD17B10TP53SMN1; SMN2KDM4EHTT
SCHEMBL6539046 0.86 TP53 (0.45) HSD17B10TP53SMN1; SMN2KDM4EHTT
SCHEMBL6538310 0.85 BRD4 (0.42) TP53KDM4EHTTMEN1KMT2A
SCHEMBL6538899 0.84 TP53 (0.43) HSD17B10TP53SMN1; SMN2KDM4EHTT
SCHEMBL6538395 0.83 TP53 (0.52) HSD17B10TP53SMN1; SMN2KDM4EHTT
SCHEMBL6539022 0.82 TP53 (0.42) TP53KDM4EHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 HSD17B10 2417/4885TP53 3830/4885SMN1; SMN2 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.